Open access
Jul 2026
Chronic oral cannabidiol delays seizure onset and reduces seizure burden in a mouse model of CLN2 disease
It is shown that chronic treatment with cannabidiol confers significant anti-seizure benefit to the mouse model of CLN2 disease, and that it does not appear to do so by altering the inflammatory and neuroimmune markers traditionally used to track CLN2 disease progression.
Joshua T. Dearborn, Keigo Takahashi, N. Rensing et al.
· PLoS ONE · 0 citations